Total joint replacement is a highly successful surgical procedure for treatment of patients with disabling arthritis and joint dysfunction. However, over time, with high levels of activity and usage of the joint, implant wear particles are generated from the articulating surfaces. These wear particles can lead to activation of an inflammatory reaction, and subsequent bone resorption around the implant (periprosthetic osteolysis). Cells of the monocyte/macrophage lineage orchestrate this chronic inflammatory response, which is dominated by a pro-inflammatory (M1) macrophage phenotype rather than an anti-inflammatory pro-tissue healing (M2) macrophage phenotype. While it has been shown that interleukin-4 (IL-4) selectively polarizes macrophages towards an M2 anti-inflammatory phenotype which promotes bone healing, rather than inflammation, little is known about the time course in which this occurs or conditions in which repolarization through IL-4 is most effective. The goal of this work was to study the time course of murine macrophage polarization and cytokine release in response to challenge with combinations of polymethyl methacrylate (PMMA) particles, lipopolysaccharide (LPS) and IL-4 in vitro. Treatment of particle-challenged monocyte/macrophages with IL-4 led to an initial suppression of pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS) production and subsequent polarization into an M2 anti-inflammatory phenotype. This result was optimized when IL-4 was delivered before PMMA particle challenge, to an M1 phenotype rather than to uncommitted (M0) macrophages. The effects of this polarization were sustained over a 5-day time course. Polarization of M1 macrophages into an M2 phenotype may be a strategy to mitigate wear particle associated periprosthetic osteolysis.
INTRODUCTION
A common and effective treatment for severe end-stage arthritis and joint dysfunction is total joint replacement. Usage of a total joint replacement leads to wear and the generation of particulate debris from the articulating surfaces. Phagocytosis of this wear debris by monocyte/macrophages leads to their activation, proliferation, and differentiation into pro-inflammatory M1 macrophages in the periprosthetic tissues. This chronic inflammatory reaction reduces bone formation and increases bone resorption, a process known as periprosthetic osteolysis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Periprosthetic bone loss leads to subsequent implant loosening, often requiring revision surgery.
The ingestion of polymer wear particles such as polymethyl methacrylate (PMMA) and polyethylene particles leads to the production of pro-inflammatory cytokines and chemokines, and the systemic migration of monocyte/macrophage precursors to the particle location. [18] [19] [20] [21] The presence of macrophages in the periprosthetic tissues is of a predominantly M1 phenotype. 22 The induction and activation of these macrophages leads to an acute inflammatory reaction, tipping the balance against the functions of the alternatively activated M2 macrophages, which include bone and wound healing, and angiogenesis. [23] [24] [25] [26] [27] While macrophage diversity includes a large spectrum of phenotypes, rather than distinctly pro-inflammatory or anti-inflammatory populations, differing cytokine production profiles have been described for M1 and M2 macrophages. 28 The cytokine release profile of M1 pro-inflammatory macrophages includes increased tumor-necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-12, IL-23 and type 1 interferon, as well as expression of inducible NO synthase (iNOS), CCR7 and HLA-DR. [29] [30] [31] [32] [33] [34] The cytokine release profile of M2 anti-inflammatory macrophages includes increased IL-4, IL-10, IL-13, and IL-1ra production, as well as expression of CD206, Ym1, CD163, CCL1, CCL18, FIZZ1, Arginase 1 and chitotriosidase. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] These distinctions provide a useful tool to identify the phenotype of the different macrophage population in tissue specimens or in vitro studies. In addition, exogenous delivery of specific cytokines, may provide the potential to stimulate a targeted response, both for purposes of study, and for future clinical intervention. 39 The effects of LPS in inducing macrophage differentiation into an M1 phenotype, and the effect of IL-4 and IL-13 in inducing macrophage differentiation into an M2 phenotype have been well established. [40] [41] [42] [43] [44] Recent studies have begun to examined the effects of these factors in the presence of wear particles. Rao et al. 22 have shown the ability to alter the phenotype of wear particle challenged macrophages through the addition of IL-4. The addition of the anti-inflammatory cytokine IL-4 led to an increase in M2 macrophage polarization by 7 days after PMMA particle challenge in vitro. IL-4 mitigated wear particle induced osteolysis through the preferential polarization of macrophages to an M2 phenotype using the murine calvarial model. 45 This work suggests the possibility for direct clinical translational application, however the conditions and time course in which IL-4 is most effective in polarizing macrophages to an M2 phenotype, even in the presence of wear particles, remain unclear. To address this question in this study, IL-4 was administered to uncommitted (M0) monocyte/ macrophages, as well as macrophages pre-treated to promote M1 or M2 polarization before particle challenge. The kinetics of the effects of IL-4 administration on macrophage polarization was assessed at multiple time points through 5 days in vitro.
The ability to minimize the inflammatory immune response and enhance bone healing and repair may prove valuable in maximizing the longevity of artificial joints. This may be possible, through the manipulation of macrophage polarization, by stimulating the conversion of monocytes/macrophages into the M2 phenotype using IL-4. The goal of this work was to challenge murine macrophages in vitro with polymethyl methacrylate particles, lipopolysaccharide (LPS) and IL-4 and to characterize the cytokine release profile and macrophage polarization over time using enzyme-linked immunosorbent assays (ELISA), real-time PCR and flow cytometry.
MATERIALS AND METHODS
Macrophage cell culture All experimental protocols have been approved by the Stanford Administrative Panel for Laboratory Animal Care. To harvest bone marrow macrophages, bone marrow cells were collected from the femora and tibiae of 15 Jackson C57BL/6J mice aged 8-10 weeks old. 46 The mice were killed with CO 2 gas, and sterilized in 70% ethanol three times for 5 min each. Under sterile conditions, the femora and tibiae of the mice were surgically removed. Using a 25-gauge needle, the bone marrow was flushed into a 50 ml centrifuge tube by injecting 5 ml of basal medium (RPMI Medium 1640 supplemented with 10% fetal bovine serum, 1% Antibiotic-Antimycotic (Invitrogen, Grand Island, NY, USA)) into the marrow cavity. The cells were filtered through a 100 um cell strainer into another 50 ml centrifuge tube. The cells were spun down and resuspended in ice cold red blood cell lysis buffer (Invitrogen) for 2 min at 4 uC, followed by the addition of basal medium. The cells were spun down again and resuspended in augmented basal medium supplemented with 30% leukocyte-conditioned medium (LCM) (v/v) and 10 ng/ml macrophage colony-stimulating factor. LCM, an important source of multiple forms of colony stimulating factors, was harvested as supernatant from the culture of L929 cells, to promote macrophage proliferation and differentiation. 47, 48 The cells were counted using a hemocytometer, and plated into 175 cm 2 culture flasks (BD, Franklin Lakes, NJ, USA) at a concentration of 50310 6 cells per flask. Culture medium was changed every 3 days for 1 week, to remove unattached cells, as the cells were allowed to reach confluency. Cells were lifted with 0.25% Trypsin/EDTA (Invitrogen), washed and resuspended in augmented basal media. Seven groups were defined, each with specific pre-treatment and treatment conditions. For subsequent ELISA and RT-PCR experiments, cells were plated in 24-well culture plates (BD, Franklin, Lakes, NJ, USA) at an initial concentration of 1310 5 cells per well, into their appropriate pre-treatment condition. For subsequent flow cytometry experiments, cells were plated in 10 cm culture dishes at an initial concentration of 1310 6 cells per dish, into their appropriate pre-treatment condition.
PMMA particle preparation Phagocytosable PMMA particles (Polysciences, Warrington, PA, USA), 1-10 mm in diameter, were sterilized in 70% ethanol three times for 10 min each and incubated overnight in 70% ethanol with shaking. The following day, the particles were washed three times with phosphate-buffered saline, and maintained at a stock solution of 5% (v/v). The particles tested negative for the presence of endotoxin using the Limulus Amoebocyte Lysate Assay (Cat# QCL-1000; Biowhittaker, Walkersville, MD, USA). A final does of 0.15% (v/v) of PMMA particles was used, as per previous studies. 16, 22 Macrophage stimulation The plated cells underwent 6 days of pre-treatment, with media changed on day 3, followed by up to 5 days of treatment. Use of a 5-day time course allowed for the detailed analysis of gene expression and cytokine release over time without the need for media changes or repeated treatment administrations. [49] [50] [51] [52] The time course and concentrations of LPS and IL-4 used to induce M1 or M2 macrophage polarization were chosen according to previous studies. 22, 32, [53] [54] [55] [56] [57] [58] [59] Seven pre-treatment and treatment groups were defined (Table 1) . Group I served as a negative control, with the macrophages receiving no stimuli. Group II tested the effects of stimulation with PMMA particles. Groups III and IV were used to study the role of LPS and IL-4, respectively, on undifferentiated macrophages. Group V tested the ability of IL-4 to alter the polarization of undifferentiated macrophages, even in the presence of two pro-inflammatory stimuli: PMMA particles and LPS. Similarly, Group VI tested whether pre-treatment of macrophages toward an M1 phenotype with LPS would optimize or hinder macrophage repolarization using IL-4, even in the presence of PMMA particles and LPS. Group VII tested whether pre-treatment of macrophages towards an M2 phenotype with IL-4 after LPS administration would mitigate the pro-inflammatory effects of PMMA particles.
Groups I-V received no pre-treatment defined as only LCM media for 6 days. Group VI received only LCM media for days 0-3, followed by LCM media1LPS (1 mg/ml) for days 3-6. Group VII received LCM media1LPS (1 mg/ml) for days 0-3, followed by LCM media1IL-4 (20 ng/ml) for days 3-6. After completion of pre-treatment on day 6, seven treatment groups were the defined as follows, to study the effect of IL-4 in the presence of the pro-inflammatory stimulus PMMA particles: (i) LCM media only; (ii) LCM media1PMMA particles (0.15% v/v); (iii) LCM media1PMMA particles (0.15% v/v)1LPS (1 mg/ml); (iv) LCM media1PMMA particles (0.15% v/ v)1IL-4 (20 ng/ml); (v) LCM media1PMMA particles (0.15% v/v)1LPS (1 mg/ml)1IL-4 (20 ng/ml); (vi) LCM media1PMMA particles (0.15% v/v)1LPS (1 mg/ml)1IL-4 (20 ng/ml); and (vii) LCM media1PMMA particles (0.15% v/v). The culture media were collected at 6, 16, 24, 48, 72 and 120 h after treatment, and analyzed for cytokine release using ELISA. At these time points, RNA was extracted by the TRIzol method and quantified by real-time PCR as described below.
ELISA
Cytokine production, reflective of the pro-inflammatory and anti-inflammatory functions of M1 and M2 macrophages, respectively, was assessed using ELISA. ELISA kits for TNF-a were purchased from Biolegend (San, Diego, CA, USA) and ELISA kits from IL-1ra were purchased from R&D Systems (Minneapolis, MN, USA). Protocols followed those provided by each manufacturer. ELISAs were run in duplicate.
RNA extraction and RT-PCR
After harvesting the cell culture media, 200 ml of TRIzol reagent (Invitrogen) was used per well to extract RNA from the macrophages according to the manufacturer's protocol. Due to low RNA quantities per well, the TRIzol extractions from three identically prepared wells were pooled prior to RNA purification. The extracted RNA was then purified using the RNeasy Mini Kit (Qiagen). The purified RNA was reverse transcribed into complementary DNA using a high-capacity complementary DNA reverse transcription kit (Applied Biosystems, Grand Island, NY, USA). Predesigned probes for 18S (Mm03928990_g1), TNF-a (Mm00443258_m1), IL-1ra (Mm00446186_m1), IL-1b (Mm00 434228_m1), IL-10 (Mm00439614_m1), RANK (Mm0043 7135_m1) and osteoprotegerin (OPG) (Mm01205928_m1) were purchased from Applied Biosystems (Grand Island, NY, USA). 18S was used as the housekeeping gene. Real-time PCR was performed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Reactions were run in triplicate, using the 18S rRNA housekeeping gene as an internal control. Expression data was normalized to the geometric mean of 18S, and relative gene expression levels analyzed using the 2 {DDC T method. 60 Flow cytometry Fluorescence-activated cell sorting was used to quantitatively assess the change macrophage populations in response to PMMA particles, LPS and IL-4 over time. F4/80 and CD11b were used as pan-macrophage markers, iNOS as a marker of M1 macrophages, CD206 as a marker of M2 macrophages, and ethidium monoazide for exclusion of dead cells. 55, [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] The cells were trypsinized and scraped from the 10 cm dishes, centrifuged and resuspended in fluorescence-activated cell sorting staining buffer (phosphate-buffered saline supplemented with 2% fetal bovine serum). The cells were incubated in mouse Fc block (rat anti-mouse CD16/C32; BD Pharmigen, San Diego, CA, USA) at a concentration of 1 : 50 for 15 min. The cells were then incubated with APC-conjugated anti-F4/80 (eBioscience, San Diego, CA, USA) at a concentration of 1 : 100, PE-Cy7 conjugated antiCD11b (eBioscience) at a concentration of 1 : 50, PE-conjugated anti-CD206 (Biolegend, San Diego, CA, USA) at a concentration of 1 : 100, and ethidium monoazide at a concentration of 1 : 2500, or their appropriate isotype controls, for 10 min in the dark followed by 10 min under direct light. The cells were centrifuged, and resuspended with fixation/permeabilization solution (BD) for 20 min at 4 uC. The cells were washed twice in Perm/Wash buffer (BD), then incubated at 4 uC with FITCconjugated anti-iNOS (BD) at a concentration of 1 : 50 for 30 min. The cells were washed twice more with Perm/Wash buffer, then resuspended in fluorescence-activated cell sorting staining buffer. Forward and side scatter gating was set to include viable cells. Viable cells were then gated to include only macrophages, defined as F4/80-positive and CD11b-positive cells. Macrophages were gated to distinguish M1 and M2 positive and negative populations. M1 macrophages were defined as iNOS-positive, CD206-negative cells. M2 macrophages were defined as iNOS-negative, CD206-positive cells. The absolute number of macrophages of various populations was calculated, and the ratio of M2/M1 macrophages taken. Sorting was done using a BD LSR II flow cytometer, and analyzed by FlowJo software (TreeStar, Ashland, OR, USA).
Statistical analysis
ELISA data was analyzed using a two-way analysis of variance to test for significance followed by Tukey multiple comparisons tests to compare treatment groups within time points using Prism 6.0 (Graphpad Software, La Jolla, CA, USA). P values less than 0.05 were considered significant. Data were reported as mean6standard error.
RESULTS

Effects of pre-treatment conditions
To study the effects of IL-4 administration on macrophage response to wear particles, macrophages were first pre-treated according to their group designation (Table 1) , and analyzed for the relative expression of multiple cytokines and the release of TNF-a and IL-1ra using real-time PCR and ELISA. All groups were analyzed on day 6, after pre-treatment was complete, and before treatment conditions. Group VI cells, which received 3 days pre-treatment with LPS, showed greatly elevated expression levels of the pro-inflammatory cytokine IL1b mRNA relative to control cells receiving only LCM media ( Figure 1a ). These cells also showed increases in TNF-a, IL-1ra, and IL-10 mRNA expression. Macrophages that received pretreatment with LPS followed by IL-4 showed increased mRNA expression levels of IL-1ra and OPG compared to control, and a reduction in IL-1b and TNF-a expression compared to LPS treatment alone (Figure 1a ). The dramatic increase in IL-1b mRNA expression following LPS exposure suggests increased differentiation into M1 macrophages in Group VI, with increases in anti-inflammatory cytokines IL-1ra and Il-10 likely due to increased feedback regulatory mechanisms. The large reduction in IL-1b mRNA expression after IL-4 administration, while maintaining some increased expression of IL-1ra may suggest a move away from a predominant M1 phenotype, towards an M2 phenotype. Cell culture supernatants were analyzed using ELISA for the release of the pro-inflammatory cytokine TNF-a, and the antiinflammatory cytokine IL-1ra. Pre-treatment with LPS led to significant increases in TNF-a release suggestive of M1 polarization, which was suppressed by subsequent addition of IL-4 in Group VII (Figure 1b) . Similar to the results analyzing gene expression, IL-1ra release was significantly increased in both pre-treatment conditions, more so in Group VI (Figure 1c) .
Within a dynamic system macrophages are receiving a balance of both pro-inflammatory and anti-inflammatory signals, with the dominant signals determining the primary response and other signals maintained for regulation of that response. As a reflection of this balance, we analyzed the effects of these pre-treatment conditions on the ratio of IL-1ra to TNF-a release. While LPS pre-treatment increased both TNF-a and IL-1ra release individually, the IL-1ra/TNF-a ratio did not change significantly (Figure 1d ). The decrease in the ratio is reflective of the large increase in TNF-a release, and a more pro-inflammatory environment. Pre-treatment with IL-4 after LPS, however, led to a significant increase in IL-1ra/TNF-a ratio suggestive of anti-inflammatory macrophage polarization. Therefore, Group VI pre-treatment led to increased M1 macrophage polarization, and Group VII pre-treatment to increased M2 macrophage polarization.
Effects of IL-4 administration on cytokine gene expression profiles After pre-treatment, macrophages were treated with the appropriate combination of PMMA particles, LPS and IL-4, and their mRNA gene expression profiles analyzed over a time course ranging from 6 h to 5 days using real-time PCR. mRNA expression is calculated relative to Group I mRNA expression. Expression levels of the pro-inflammatory cytokines TNF-a and IL-1b peaked at 6 and 16 h post treatment, respectively, followed by a large and sustained decrease in all treatment conditions (Figure 2a and c) . The expression of both TNF-a and IL-1b increased with PMMA administration alone in Group II, and was greatest when stimulated with both PMMA particles and LPS in Group III. IL-4 administration in the presence of both PMMA and LPS, as in Group V, was not sufficient to mitigate a strong pro-inflammatory state. After pre-treatment to M1 macrophages in Group VI, however, IL-4 further reduced TNF-a and IL-1b expression. IL-4 was most effective in suppressing the expression of pro-inflammatory cytokines when undifferentiated or pre-treated M2 macrophages were challenged with PMMA particles alone, as in Group VII (Figure 2a and c) .
Gene expression levels of the anti-inflammatory cytokines IL-1ra and IL-10 also showed early peaks, at 6 and 24 h post treatment, respectively, although with slightly different expression patterns (Figure 2b and d) . As seen with the pretreatment gene expressions, pro-inflammatory treatment groups such as Groups III and Group V, also increased antiinflammatory cytokine expression, likely as part of a regulatory process. IL-4 administration to undifferentiated macrophages in Group IV, did not lead to a large increase in IL-1ra or IL-10 expression. The effective suppression of an inflammatory state may not have necessitated a large increase in anti-inflammatory cytokine expression. Similarly, in Group VII, the addition of PMMA particles to M2 macrophages led to a modest increase in IL-1ra expression but low IL-10 expression (Figure 2b and  d) .
RANK-L, through interaction with RANK, stimulates osteoclast formation from monocyte/macrophage precursors leading to increased bone resorption. OPG acts as a RANK-L decoy receptor, serving to prevent interaction of RANK-L and RANK, thereby decreasing osteoclast formation. Evaluation of RANK and OPG mRNA expression in the various treatment conditions varied notably over the 5-day time course. No clear pattern for the effects of IL-4 administration on RANK or OPG expression emerged.
Effects of IL-4 administration on cytokine release
After treatment, the cell culture media were analyzed for TNFa and IL-1ra release using ELISA. Treatment with LPS and PMMA particles in Group III led to significant increases in TNF-a release relative to Group I and Group VII within 6 h (Figure 3a) . By 16 h, Group III LPS and PMMA particle treatment led to significantly higher TNF-a release than all other treatment conditions. As seen in Group V, concurrent administration of IL-4 with LPS and PMMA without pre-treatment was again unable to significantly suppress the effects of proinflammatory stimuli. However, with prior pre-treatment to M1 macrophages in Group VI, TNF-a release was significantly decreased. As seen previously, the lowest TNF-a levels after particle stimulation were achieved when the wear particles were placed into an already anti-inflammatory environment in Group VII (Figure 3a) .
Unlike the gene expression results, the greatest IL-1ra release is seen with IL-4 administration, particularly as pre-treatment to particle challenge (Figure 3b ). While proinflammatory experimental groups such as Groups III and V show high early IL-1ra release, it was suppressed by 48 h, and maintained at a lower concentration. IL-4 treatment groups following M1 pre-treatment, however, showed steady increases in IL-1ra concentration, with Group VII reaching significantly higher release than Groups I, II and IV by 48 h post treatment, and maintained that increase through the 5-day time course (Figure 3b) . Macrophages pre-treated with a pro-inflammatory stimulus and converted to an M1 phenotype before IL-4 administration and particle challenge in Group VII showed the greatest increase in the ratio of IL1ra to TNF-a secretion. The levels approached or surpassed Figure 1 Pre-treatment with LPS or LPS then IL-4 resulted in M1 and M2 macrophage populations, respectively. (a) Pre-treatment for 3 days with LPS (1 mg/ml) resulted in increased mRNA expression of IL-1b relative to no pre-treatment, and to a lesser extent anti-inflammatory cytokines, as analyzed by real-time PCR. Subsequent 3-day pre-treatment with IL-4 greatly reduced the mRNA expression of both pro-inflammatory cytokines TNF-a and IL-1b, and anti-inflammatory cytokines IL-1ra and IL-10, while increasing OPG expression. (b, c) TNF-a and IL-1ra secretion were analyzed by ELISA. LPS pre-treatment led to increased TNF-a secretion suggestive of M1 phenotype polarization, which was suppressed after IL-4 administration. Both LPS and IL-4 pre-treatment led to increased production of IL-1ra. (d) IL-4 administration after LPS pre-treatment led to increased IL-1ra/TNF-a ratio showing an increase in the release of anti-inflammatory cytokines relative to pro-inflammatory cytokines beyond that expected solely for regulatory purposes (n53 per group). *Pf0.05, **Pf0.01, ***Pf0.001. ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LPS, lipopolysaccharide; OPG, osteoprotegerin; PCR, polymerase chain reaction; TNF, tumor-necrosis factor. the normal and fluctuating balance evident in control Group I, suggesting a suppression of the inflammatory response (Figure 3c ). Notable differences were seen between the mRNA and protein expression of TNF-a and IL-1ra including differences in peak expression during the time course. This may be explained Figure 3 IL-4 administration leads to a preferential increase in IL-1ra secretion relative to TNF-a, suggestive of polarization toward an M2 phenotype. TNF-a and IL-1ra secretion was measured by ELISA. (a) Stimulation with LPS led to significant increases in TNF-a production (* at 6 and 120 h; *** at 16, 24, 48 and 72 h). IL-4 delivered concurrent with PMMA particle and LPS stimulation without pre-treatment in Group V was unable to suppress TNF-a levels, secreting elevated levels of TNF-a relative to all groups except Group III (*** at 16 h; ** at 24 h; * at 72 h). IL-4 administered to undifferentiated macrophages in Group IV, or macrophages pre-treated with LPS in Groups VI-VII, effectively lowered TNF-a production for the duration of the time course relative to LPS-treated macrophages (*** at 16 and 48 h; ** at 24 and 72 h; * at 120 h). (b) Pretreatment of macrophages with IL-4 prior to particle challenge in Group VII led to a steady and significant increase in IL-1ra production relative to all groups without pre-treatment by 5 days post treatment (***). (c) By 5 days after treatment, IL-4 pre-treatment in Group VII led to increased IL-1ra/ TNF-a ratio relative to all particle-treated groups without pre-treatment (**). This finding suggests an increase in the release of anti-inflammatory by intrinsic differences between the testing methods. The results of mRNA expression show the transcripts present at the specific moment of collection, while analysis of cytokine secretion by ELISA measures the total concentration of the individual cytokine, whether the protein was secreted immediately before collection or hours earlier. Although the half-life of cytokines is thought to be extremely short in vivo, cytokines in cell culture experiments have been shown to last far longer, on the order of hours. 75 Therefore results of in vitro studies suggest recent rather than immediate cell activity. Similarly, as mentioned, the groups showing the highest IL-1ra expression differed between the mRNA and protein levels. It is thought that IL-1ra, TNF-a and other cytokines are regulated not only at the transcriptional level, but also through post-transcriptional modifications regulated by a 39-untranslated region. 76, 77 Changes in post-transcriptional modification due to differing pro-inflammatory or anti-inflammatory environments may impact the efficiency or extent of translation to functional protein.
Analysis of macrophage populations by flow cytometry
In addition to their differing cytokine release profile, M1 and M2 macrophages are characterized by the regulation of intracellular and surface proteins. To further assess the ability of IL-4 to repolarize macrophages toward an M2 phenotype in the presence of wear particles, flow cytometry was used to analyze the macrophage populations present in the various treatment groups at 6, 24 and 72 h. Macrophages were defined as cells positive for pan-macrophage markers F4/80 and CD11b. Within the macrophage population, M1 macrophages were defined as iNOS-positive, CD206-negative cells, and M2 macrophages as iNOS-negative, CD206-positive cells. Group II macrophages challenged with PMMA particles without pretreatment showed higher levels of iNOS expression after 6 h of treatment relative to Group VII cells pre-treated with LPS then IL-4 before particle challenge (Figure 4a) . By 72 h, total levels of iNOS expression were similar between the treatment groups ( Figure 4b ). Alternatively, 6 h post treatment, the proportion of CD206-positive cells was similar across both treatment groups (Figure 4c) . By 72 h, macrophages pre-treated with IL-4 showed greater expression of CD206 (Figure 4d ). These findings suggest IL-4 may lead to a rapid suppression of proinflammatory factors, followed by a subsequent increase in anti-inflammatory markers.
As with the analysis of pro-inflammatory and anti-inflammatory cytokines, it is important to consider shifts in the balance between M1 and M2 markers. When the ratio of the absolute numbers of M2 to M1 macrophages was taken, groups with IL-4 administration after pre-treatment again showed no particular increases in M2 macrophages at 6 h post treatment. By 72 h after treatment, Groups VI and VII showed increasingly higher M2 macrophages relative to other treatment groups (Figure 4e) . As seen by ELISA analysis of cytokine release, treatment of undifferentiated macrophages with IL-4 in Groups IV and V did not lead to sustained increases in M2 populations, suggesting repolarization using IL-4 may be most effective if administered to previously activated macrophages. Group III macrophages showed a large rise in CD206 expression at 24 h that was not sustained. This parallels the pattern of IL-1ra expression as detected by ELISA and real-time PCR, with a peak at 24 h with a subsequent decline, possibly serving to activate regulatory mechanisms to control the pro-inflammatory response (Figure 4e ). Many macrophages that were positive for both iNOS and CD206 were detected, possibly representing intermediate populations, or macrophages transitioning through M1 and M2 phenotypes ( Figure 4F ). Similarly, IL-4 treatment after LPS pre-treatment led to increased levels of macrophages not expressing either marker of differentiated after 72 h, suggesting a possible return towards a non-inflammatory and undifferentiated state (Figure 4g ).
DISCUSSION
This study investigated the time course of macrophage polarization in response to wear particles and IL-4 treatment in vitro. To accomplish this, bone marrow-derived macrophages were cultured for different lengths of time under various pre-treatment and treatment conditions. To test for optimal conditions in which macrophages are polarized toward an M2 phenotype, select groups of macrophages received pre-treatments leading to M1 or M2 macrophage populations. Treatment of macrophages with PMMA wear particles, with or without LPS, led to rapid increases in the expression of pro-inflammatory cytokines TNF-a and IL-1b. Costimulation of undifferentiated macrophages with PMMA particles and LPS was too powerful a pro-inflammatory stimulus to allow repolarization using IL-4. Addition of IL-4 to pre-treated M1 or M2 macrophages before or during particle challenge, however, was sufficient to markedly reduce expression of these pro-inflammatory cytokines. This inhibition was effective both initially, and throughout the 5-day time course. The greatest increases in the gene expression of the anti-inflammatory cytokines IL-1ra and IL-10 did not come from macrophages treated with IL-4, however, but those receiving the strongest activation signals. The increase in IL-1ra and IL-10 expression may serve as a regulatory mechanism to control the extent of the overall proinflammatory process. In addition, effective suppression of pro-inflammatory cytokines may reduce the signals that promote an anti-inflammatory response. Increases in IL-10 expression in macrophages stimulated with LPS has been reported in other studies. 78 Similarly, analysis of cytokine release showed increased TNF-a in groups treated with particles and LPS, even in the presence of concurrently administered cytokines relative to pro-inflammatory cytokines suggestive of increased polarization towards an M2 phenotype. *Pf0.05, **Pf0.01, ***Pf0.001. ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LPS, lipopolysaccharide; PMMA, polymethyl methacrylate; TNF, tumor-necrosis factor.
IL-4. The effects of IL-4 were greatly enhanced when administered to pre-treated M1 macrophages. TNF-a concentrations decreased, and IL-1ra progressively increased over the 5-day time course in these conditions. While macrophages receiving activation signals again increased IL-1ra levels initially, macrophages receiving IL-4 pre-treatment before particles challenge resulted in statistically significant increases in the ratio of antiinflammatory to pro-inflammatory signals.
We show an initial decrease in the prevalence of M1 macrophage markers with the addition of IL-4 using flow cytometry, suggesting suppression of pro-inflammatory functions consistent with the gene expression and cytokine release results. At these early stages, we did not observe a change in the proportion of M2 phenotype markers within the macrophage population. After 3 days of treatment, iNOS levels rose in all treatment conditions, while we also observed a greater increase in CD206 levels in IL-4 treated conditions after pre-treatment. Examination of the relative numbers of M1 and M2 macrophages showed no clear pattern initially, but by 72 h, the population in IL-4 pre-treated macrophages trended toward increased macrophages expressing the M2 phenotype.
While it serves as a useful framework to consider the various roles of macrophages throughout various tissues, the division of macrophage phenotypes strictly into M0, M1 and M2 is overly simplistic. In our study, a considerable population of macrophages was identified which coexpressed both M1 and M2 macrophage markers. Such populations has also been reported in other studies; however, the role of these macrophages have yet to be well understood. 64 While previous studies have examined the changes in macrophage markers and morphology during activation, these cells may represent previously unidentified macrophage phenotypes that should be studied further. [79] [80] [81] Our study has shown that polarization of macrophages toward an M2 phenotype through IL-4 is most effective when first pre-treated toward an M1 phenotype. As such, a subset of these cells may represent macrophages in the process of polarizing toward an M1 or M2 phenotype, upregulating CD206 and other anti-inflammatory markers while downregulating the production of iNOS and other pro-inflammatory markers. iNOS is predominantly an intracellular protein. Recent studies have shown that down-regulation of iNOS expression and suppression of nitric oxide production may be accomplished by the formation of aggresomes. [82] [83] [84] Although flow cytometry separates populations through the presence or absence of particular cell markers, the permeabilization required for detection of intracellular markers may provide access to sequestered and inactivated intracellular iNOS. Characterizing the various macrophage populations using multiple M1 and M2 markers and an extended time course of study, is likely to provide information about the roles of such cells. In addition, histological analysis of the subcellular location of pro-inflammatory and anti-inflammatory markers in double positive cells may distinguish populations functionally or transiently expressing markers of M1 and M2 phenotypes.
There are several limitations to this study. Due to low quantities of RNA extracted and purified per well, samples from three identical experiments were pooled for each experimental condition. While this allowed for the analysis of gene expression of multiple pro-inflammatory and antiinflammatory cytokines over the time course, it did not allow for statistical testing. The trends seen in the gene expression data are supported by the analysis of cytokine release by ELISA. Protein analysis was done, however, on only one representative pro-inflammatory and one antiinflammatory cytokine, TNF-a and IL-1ra, respectively. To survey the changes in macrophage populations upon particle challenge and IL-4 administration, combinations of four markers were used to identify M1 and M2 populations. While commonly used as pan-macrophage markers, neither F4/80 nor C11b are exclusively found on macrophages. F4/80 can be found on subsets of dendritic cells, and CD11b on granulocytes and subsets of T cells and dendritic cells. 61, 62 To control for the unspecific nature of these markers, multiple steps were taken. First, cultures were grown in leukocyte-conditioned medium and macrophage colony-stimulating factor to promote macrophage differentiation and proliferation. In addition, in flow cytometric analysis of the macrophage populations, only cells double positive for both F4/80 and CD11b were considered to be macrophages.
In summary, this study demonstrated that the ability to polarize macrophages toward an M2 phenotype in the presence of wear particles is optimized when M1 macrophages are treated with IL-4 prior to or concurrent with particle challenge. Initial changes are seen within the first 6 h, and are sustained or furthered over a 5-day time course. Our results suggest that IL-4 may first serve to suppress the expression and production of pro-inflammatory products that would normally be produced in response to wear particles. Subsequently, macrophages begin to increase the production of anti-inflammatory cytokines and M2 markers over time, leading to an increase in macrophages of an M2 phenotype within the population. These results lend support to the proposed benefits of local IL-4 administration in association with total joint replacements as a means of slowing the progression of periprosthetic osteolysis and promoting bone healing. Further studies are necessary, however, to provide greater understanding of the mechanisms by which macrophage populations are altered by IL-4. Recent work by Tang et al. [85] [86] [87] have shown the ability to detect and monitor activated macrophages and neutrophils in real time in vivo through the use of NIR nanoprobes. This technology, along with probes targeted for alternatively activated macrophages, may be combined with established in vivo models of particle-induced osteolysis. 45 These studies may provide more detailed insight into the mechanisms by which IL-4 affects macrophage populations and the subsequent impact of these changes on bone loss or repair.
